Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of

Analyst Ratings Synthesis

Consensus is Buy across five analysts, with a mean price target of $21 compared with the supplied ending price of $16.56. No low or high target is reported, so the target range, clustering, and breadth of disagreement cannot be measured. The supplied evidence does not identify the most bullish or least bullish analyst, and it records no rating or target revisions during the past week. The substantive investment tension is between Takeda’s portfolio transition and the ongoing decline of mature products: the earnings-call summary says core brands and newer products largely offset that pressure, while the stock’s 5.48% weekly decline indicates that this offset has not convinced the market of stronger near-term momentum.

• Takeda Pharmaceutical Q1 Earnings Call Highlights